Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 2/20 | 0.33 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.33 |
| ▸ | IKBKB | O14920 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 4/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9975727 | 0.96 | CHRM2 (0.34) | NR1I2CYP2E1CHRM2CHRM4CHRM5 | |
| SCHEMBL9975840 | 0.95 | CHRM2 (0.35) | NR1I2CYP2E1CHRM2CHRM4CHRM5 | |
| SCHEMBL10324385 | 0.92 | NR1I2 (0.34) | NR1I2CYP2E1IKBKB | |
| SCHEMBL9975765 | 0.89 | NR1I2 (0.33) | NR1I2CYP2E1CHRM2CHRM4CHRM5 | |
| SCHEMBL9975680 | 0.88 | NR1I2 (0.45) | NR1I2CYP2E1CHRM2CHRM4CHRM5 | |
| SCHEMBL9975844 | 0.87 | NR1I2 (0.39) | NR1I2CYP2E1CHRM2CHRM4CHRM5 | |
| SCHEMBL19402934 | 0.87 | CHRM2 (0.33) | IKBKBCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL19135645 | 0.86 | CHRM2 (0.34) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL9975688 | 0.86 | NR1I2 (0.32) | NR1I2CYP2E1CHRM2CHRM4CHRM5 | |
| SCHEMBL9975772 | 0.86 | CHRM5 (0.32) | NR1I2CYP2E1CHRM2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140322165-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL DISCOVERY INC (US) | 2014-10-30 | — | — | US | disclosed |
| US-20140322165-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL DISCOVERY INC (US) | 2014-10-30 | — | — | US | disclosed |
| US-20140322165-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL DISCOVERY INC (US) | 2014-10-30 | — | — | US | disclosed |
| US-8771665-B2 | Inhibitors of hepatitis C virus polymerase | COCRYSTAL DISCOVERY, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-8771665-B2 | Inhibitors of hepatitis C virus polymerase | COCRYSTAL DISCOVERY, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-8771665-B2 | Inhibitors of hepatitis C virus polymerase | COCRYSTAL DISCOVERY, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20120183496-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL DISCOVERY, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120183496-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL DISCOVERY, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| WO-2012083105-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL DISCOVERY, INC. (US) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120183496-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | POLR2A, POLR2B, POLR2E | NR1I2 126/4885CYP2E1 142/4885IKBKB 468/4885 |
| US-20140322165-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | POLR2A, POLR2B, POLR2E | NR1I2 126/4885CYP2E1 142/4885IKBKB 468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.